SKG0977

SKG0977 is an investigational gene therapy being developed by Xiamen Tebao Biological Engineering (also known as Amoytop Biotech) for the treatment of hereditary myopathies, with a specific focus on Duchenne muscular dystrophy (DMD). Currently in the preclinical stage, SKG0977 is designed as a potential first-line treatment that aims to address the underlying genetic cause of muscle degeneration. As a gene therapy, it likely functions by delivering a functional transgene to muscle cells to compensate for the lack of endogenous dystrophin, thereby restoring muscle structural integrity and improving motor function in patients with these genetic disorders.